RBC Capital Starts Climb Bio (CLYM) at Outperform
Tweet
Share
E-mailGet Alerts CLYM Hot Sheet
Price: $11.90 --0%
Rating Summary:
15 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 10 | New: 9
Rating Summary:
15 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 10 | New: 9
Join SI Premium – FREE
RBC Capital initiates coverage on Climb Bio (NASDAQ: CLYM) with a Outperform rating and a price target of $23.00.
For an analyst ratings summary and ratings history on Climb Bio click here. For more ratings news on Climb Bio click here.
Shares of Climb Bio closed at $11.90 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- William Blair Downgrades Birkenstock Holding plc (BIRK) to Market Perform
- Loop Capital Assumes Williams-Sonoma (WSM) at Buy
- Goldman Monthly Update to US Director's Cut List
Create E-mail Alert Related Categories
New CoverageRelated Entities
RBC Capital, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
